Crystal form of Wee1 inhibitor compound and its application
The development of crystalline forms of a compound addresses the stability and solubility challenges of existing Wee1 inhibitors, resulting in enhanced therapeutic efficacy for treating Wee1-related diseases by providing stable and highly soluble pharmaceuticals.
Patent Information
- Application Number
- JP2021564588
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-30
- Filing Date
- 2020-04-30
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2040-04-30
AI Technical Summary
Current Wee1 inhibitors, such as AZD1775, face challenges in effectively targeting cancer cells with mutations in the G2/M checkpoint, leading to incomplete DNA repair and treatment resistance, necessitating the development of more stable and effective crystalline forms for enhanced therapeutic efficacy.
The invention provides five distinct crystalline forms (A, B, C, D, E, and F) of a compound of formula (I), characterized by specific X-ray powder diffraction and thermal analysis patterns, which exhibit stability and high solubility, facilitating the production of pharmaceuticals for targeting Wee1-related diseases.
The crystalline forms of the compound demonstrate improved stability, solubility, and therapeutic efficacy, enhancing the treatment of Wee1-related diseases by stabilizing the compound against light, heat, and humidity, and improving pharmacokinetic properties.
Smart Images

Figure 0007582970000034 
Figure 0007582970000035 
Figure 0007582970000036
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS CN201910364694.X, application date: April 30, 2019.
[0002] The present invention discloses a crystalline form of the compound of formula (I) and its application in the manufacture of a medicament for treating Wee1 related diseases. [Background technology]
[0003] The cell cycle process is a complex process controlled by a series of cell cycle control systems. The core components of the cell cycle control system are the CDKs / Cyclins complexes formed by the binding of cyclin-dependent kinases (CDKs) and cyclins. These complexes can promote cells to enter the proliferation cycle, and the CDK1 (human homologue is also called CDC2) / Cyclin B complex plays an important role in controlling cells to enter the M phase.
[0004] Before cells can enter the M phase, DNA replication must be completed. DNA is constantly mutated or damaged due to interference from a variety of endogenous and exogenous factors. Such abnormal DNA must be repaired or it will undergo mitotic collapse, resulting in cell death.
[0005] The main function of cell cycle checkpoints is to pause the cell cycle and allow cells to complete DNA repair and enter the M phase. The G1 / S checkpoint at the end of G1 and the G2 / M checkpoint at the G2 phase are the two main cell cycle checkpoints, both responsible for the identification and repair of DNA damage. Normal cells can complete DNA repair in the G1 phase by the G1 / S checkpoint, but about 50% of cancer cells have a tumor suppressor gene p53 defect, which also causes them to lose the function of the G1 / S checkpoint at the same time, and they must rely heavily on the G2 / M checkpoint to complete DNA repair. Mutations rarely occur in the G2 / M checkpoint, which allows cancer cells to escape treatment with DNA damaging agents and radiation.
[0006] Wee1 protein kinase is a cell cycle regulator, a member of the nuclear serine and threonine protein kinase family, and an important kinase of the G2 / M checkpoint. The human "Wee" protein kinase family mainly includes two types, Wee1 and Myt1, both of which can phosphorylate the Tyr15 site of CDC2 to inhibit the activation of the CDC2 / CyclinB complex and prevent cells from entering the M phase until DNA repair is completed. Myt1 can also phosphorylate the Thr14 site of CDC2, which also negatively regulates CDC2 activity. Wee1 kinase is highly expressed in multiple cancer cells, and by inhibiting Wee1 kinase, tumor cells can directly skip DNA repair in the G2 phase and proceed to mitosis, causing tumor cell death and achieving the purpose of treating cancer.
[0007] At present, AstraZeneca's Wee1 inhibitor AZD1775 has entered clinical phase II, more than 30 clinical trials have been developed, and it shows good therapeutic effect.AZD1775 is also called MK-1775, because it was developed by Merck first.In September 2013, Merck transferred this compound to AstraZeneca worldwide, and its related patents are mainly US20070254892, WO2007126122, EP2213673, WO2008133866, WO2011034743, etc. Abbott and Abbvie are also researching Wee1 inhibitors, and their related patents are mainly US2012220572, WO2013126656, WO2013012681, WO2013059485, WO2013013031, WO2013126656, etc. Almac's patents related to Wee1 inhibitors include WO2014167347, WO2015019037, and WO2015092431.
[0008] WO2008133866 discloses the compound AZD1775, the structure of which is shown below: [ka] [Prior art documents] [Patent documents]
[0009] [Patent Document 1] US Patent Publication No. 20070254892 [Patent Document 2] International Publication No. 2007126122 [Patent Document 3] European Patent No. 2213673 Specification [Patent Document 4] International Publication No. 2008133866 [Patent Document 5] International Publication No. 2011034743 [Patent Document 6] US Patent Publication No. 2012220572 [Patent Document 7] International Publication No. 2013126656 [Patent Document 8] International Publication No. 2013012681 [Patent Document 9] International Publication No. 2013059485 [Patent Document 10] International Publication No. 2013013031 [Patent Document 11] International Publication No. 2014167347 [Patent Document 12] International Publication No. 2015019037 [Patent Document 13] International Publication No. 2015092431 Summary of the Invention [Means for solving the problem]
[0010] The present invention provides a crystalline form A of compound of formula (I), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at 2θ angles: 5.71±0.2°, 12.68±0.2° and 15.32±0.2°.
[0011] [ka]
[0012] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form A has characteristic diffraction peaks at the following 2θ angles: 5.71±0.2°, 12.68±0.2°, 15.32±0.2°, 19.72±0.2°, 21.44±0.2°, 23.61±0.2° and 25.68±0.2°.
[0013] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form A has characteristic diffraction peaks at the following 2θ angles: 5.71±0.2°, 12.68±0.2°, 15.32±0.2°, 18.04±0.2°, 19.72±0.2°, 21.44±0.2°, 23.61±0.2° and 25.68±0.2°.
[0014] In some embodiments of the present invention, the XRPD pattern of crystalline form A is shown in FIG.
[0015] In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form A is shown in Table 1.
[0016] Table 1: Analysis data of XRPD pattern of crystalline form A [Table 1]
[0017] In some embodiments of the present invention, the differential scanning calorimetry curve (DSC) of crystalline form A has single endothermic peak onsets at 34.95±3° C., 174.75±3° C., and 219.12±3° C., respectively.
[0018] In some embodiments of the present invention, the DSC pattern of crystalline form A is shown in FIG.
[0019] In some embodiments of the present invention, the thermogravimetric analysis curve (TGA) of said crystalline form A reaches a weight loss of 0.7367% at 70.33±3° C. and a weight loss of 3.123% at 209.42±3° C.
[0020] In some embodiments of the present invention, the TGA pattern of crystalline form A is shown in FIG.
[0021] The present invention provides a crystalline form B of compound of formula (I), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at 2θ angles: 5.58±0.2°, 12.44±0.2° and 22.16±0.2°.
[0022] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form B has characteristic diffraction peaks at the following 2θ angles: 5.58±0.2°, 11.71±0.2°, 12.44±0.2°, 14.48±0.2°, 15.13±0.2°, 18.64±0.2°, 22.16±0.2° and 26.33±0.2°.
[0023] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form B has characteristic diffraction peaks at the following 2θ angles: 5.58±0.2°, 11.71±0.2°, 12.44±0.2°, 14.48±0.2°, 15.13±0.2°, 17.57±0.2°, 18.64±0.2°, 22.16±0.2° and 26.33±0.2°.
[0024] In some embodiments of the present invention, the XRPD pattern of crystalline form B is shown in FIG.
[0025] In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form B is shown in Table 2.
[0026] Table 2: Analysis data of XRPD pattern of crystalline form B [Table 2]
[0027] In some embodiments of the present invention, the differential scanning calorimetry curve (DSC) of the crystalline form B has single endothermic peak onsets at 42.88±3° C., 198.79±3° C., and 222.36±3° C., respectively.
[0028] In some embodiments of the present invention, the DSC pattern of crystalline form B is shown in FIG.
[0029] In some embodiments of the present invention, the thermogravimetric analysis curve (TGA) of the crystalline form B reaches a weight loss of 3.265% at 64.21±3° C. and a weight loss of 1.516% at 243.05±3° C.
[0030] In some embodiments of the present invention, the TGA pattern of crystalline form B is shown in FIG.
[0031] The present invention provides a C crystalline form of compound of formula (I), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at 2θ angles of 5.05±0.2°, 5.58±0.2° and 12.44±0.2°.
[0032] In some embodiments of the present invention, the X-ray powder diffraction pattern of the C crystalline form has characteristic diffraction peaks at the following 2θ angles: 5.05±0.2°, 5.58±0.2°, 12.44±0.2°, 15.91±0.2°, 16.68±0.2°, 17.61±0.2°, 22.19±0.2° and 26.37±0.2°.
[0033] In some embodiments of the present invention, the XRPD pattern of crystalline form C is shown in FIG.
[0034] In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form C is shown in Table 3.
[0035] Table 3: Analysis data of XRPD pattern of crystalline form C [Table 3]
[0036] In some embodiments of the present invention, the differential scanning calorimetry curve (DSC) of the C crystalline form has single endothermic peak onsets at 37.06±3° C., 189.16±3° C., and 218.61±3° C., respectively.
[0037] In some embodiments of the present invention, the DSC pattern of the C crystalline form is shown in FIG.
[0038] In some embodiments of the present invention, the thermogravimetric analysis curve (TGA) of the C crystalline form reaches a weight loss of 2.211% at 64.98±3° C. and a weight loss of 1.127% at 224.71±3° C.
[0039] In some embodiments of the present invention, the TGA pattern of the C crystalline form is shown in FIG.
[0040] The present invention provides a D crystalline form of compound of formula (I), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at 2θ angles: 5.22±0.2°, 15.99±0.2° and 16.57±0.2°.
[0041] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form D has characteristic diffraction peaks at the following 2θ angles: 5.22±0.2°, 15.99±0.2°, 16.57±0.2° and 21.22±0.2°.
[0042] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form D has characteristic diffraction peaks at the following 2θ angles: 5.22±0.2°, 15.18±0.2°, 15.99±0.2°, 16.57±0.2°, 17.08±0.2°, 18.60±0.2°, 21.22±0.2°, and 21.89±0.2°.
[0043] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form D has characteristic diffraction peaks at the following 2θ angles: 5.22±0.2°, 15.18±0.2°, 15.99±0.2°, 16.57±0.2°, 17.08±0.2°, 17.90±0.2°, 18.60±0.2°, 21.22±0.2°, 21.89±0.2°, 25.24±0.2°, and 27.00±0.2°.
[0044] In some embodiments of the present invention, the XRPD pattern of crystalline form D is shown in FIG.
[0045] In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form D is shown in Table 4.
[0046] Table 4: Analysis data of XRPD pattern of crystalline form D [Table 4]
[0047] In some embodiments of the present invention, the differential scanning calorimetry curve (DSC) of the D crystalline form has single endothermic peak onsets at 56.07±3° C., 193.93±3° C., and 216.54±3° C., respectively.
[0048] In some embodiments of the present invention, the differential scanning calorimetry curve (DSC) of the D crystalline form has one endothermic peak onset at 56.07±3°C, 193.93±3°C, and 216.54±3°C, respectively, and one exothermic peak at 206.82±3°C.
[0049] In some embodiments of the present invention, the DSC pattern of the D crystalline form is shown in FIG.
[0050] In some embodiments of the present invention, the thermogravimetric analysis curve (TGA) of the D crystalline form reaches a weight loss of 1.977% at 79.35±3° C. and a weight loss of 1.589% at 223.66±3° C.
[0051] In some embodiments of the present invention, the TGA pattern of crystalline form D is shown in FIG.
[0052] The present invention provides a crystalline form E of the compound of formula (I), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at 2θ angles: 8.65±0.2°, 14.22±0.2° and 24.58±0.2°.
[0053] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form E has characteristic diffraction peaks at the following 2θ angles: 8.65±0.2°, 11.41±0.2°, 13.13±0.2°, 14.22±0.2°, 17.35±0.2°, 18.34±0.2°, 20.39±0.2°, 20.94±0.2°, and 24.58±0.2°.
[0054] In some embodiments of the present invention, the XRPD pattern of the E crystalline form is shown in FIG.
[0055] In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form E is shown in Table 5.
[0056] Table 5: Analysis data of XRPD pattern of crystalline form E [Table 5]
[0057] In some embodiments of the present invention, the differential scanning calorimetry curve (DSC) of the E crystalline form has onsets of one endothermic peak at 121.57±3°C, 197.26±3°C, and 217.23±3°C, respectively, and peak values of one exothermic peak at 168.31±3°C and 212.95±3°C, respectively.
[0058] In some embodiments of the present invention, the DSC pattern of the E crystalline form is shown in FIG.
[0059] In some embodiments of the present invention, the thermogravimetric analysis curve (TGA) of the E crystalline form reaches a weight loss of 6.775% at 143.31±3° C. and a weight loss of 0.3184% at 213.62±3° C.
[0060] In some embodiments of the present invention, the TGA pattern of crystalline form E is shown in FIG.
[0061] The present invention provides a crystalline form F of compound of formula (I), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at 2θ angles: 5.06±0.2°, 15.91±0.2° and 16.68±0.2°.
[0062] In some embodiments of the present invention, the X-ray powder diffraction pattern of the F crystalline form has characteristic diffraction peaks at the following 2θ angles: 5.06±0.2°, 8.34±0.2°, 10.98±0.2°, 15.13±0.2°, 15.91±0.2°, 16.68±0.2°, 17.63±0.2°, and 18.87±0.2°.
[0063] In some embodiments of the present invention, the X-ray powder diffraction pattern of the F crystalline form has characteristic diffraction peaks at the following 2θ angles: 5.06±0.2°, 8.34±0.2°, 10.98±0.2°, 15.13±0.2°, 15.91±0.2°, 16.68±0.2°, 17.63±0.2°, 18.87±0.2°, 20.33±0.2°, 21.44±0.2°, 22.01±0.2°, 24.04±0.2°, 25.32±0.2°, and 25.66±0.2°.
[0064] In some embodiments of the present invention, the XRPD pattern of crystalline form F is shown in FIG.
[0065] In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form F is shown in Table 6.
[0066] Table 6. XRPD pattern analysis data of crystalline form F [Table 6]
[0067] In some embodiments of the present invention, the differential scanning calorimetry curve (DSC) of the F crystalline form has single endothermic peak onsets at 48.69±3° C. and 225.26±3° C., respectively.
[0068] In some embodiments of the present invention, the DSC pattern of the F crystalline form is shown in FIG.
[0069] In some embodiments of the present invention, the thermogravimetric analysis curve (TGA) of the F crystalline form reaches a weight loss of 3.404% at 100±3° C.
[0070] In some embodiments of the present invention, the TGA pattern of crystalline form F is shown in FIG.
[0071] The method for producing the F crystalline form of the compound of formula (I) according to the present invention comprises the steps of: (a) adding a compound of formula (I) to an alcoholic solvent, stirring and heating to 55-65°C in an oil bath; (b) stirring at 47° C.-53° C. for 72 hours; (c) stopping the heating and allowing the mixture to cool naturally for 1 hour while stirring to reach 27°C; (d) allowing to stand for 18 hours, filtering and washing the filter cake with methanol; and (e) vacuum drying at 60° C. for 48 hours.
[0072] In some aspects of the invention, the alcoholic solvent is methanol.
[0073] The present invention further provides the use of the crystalline form A, the crystalline form B, the crystalline form C, the crystalline form D, the crystalline form E or the crystalline form F in the manufacture of a medicament for treating Wee1-related diseases. Effect of the Invention
[0074] The crystalline forms A, B, C, D, E and F of the compound of the present invention are stable, less affected by light, heat and humidity, and have very high solubility, and are promising for the production of pharmaceuticals. Definitions and Explanations
[0075] Unless otherwise stated, the following terms and phrases as used herein shall have the following meanings: Certain words or terms should not be considered unclear or indefinite, but should be understood in their ordinary sense, unless specifically defined. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredients.
[0076] The intermediate compounds of the present invention can be prepared by various synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitution forms known to those skilled in the art, and preferred embodiments include, but are not limited to, the examples of the present invention.
[0077] The chemical reactions in the specific embodiments of the present invention are completed in suitable solvents, which should be suitable for the chemical reactions of the present invention and the reagents and materials required therefor. To obtain the compounds of the present invention, those skilled in the art may need to modify or select synthetic steps or reaction flows based on the existing embodiments.
[0078] The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples in any way.
[0079] All solvents used in this invention are commercially available and can be used without further purification.
[0080] The solvents used in the present invention are commercially available. The following abbreviations are used in the present invention: DCM: dichloromethane; DMF: N,N-dimethylformamide; DMSO: dimethylsulfoxide; EtOH: ethanol; MeOH: methanol; TFA: trifluoroacetic acid; TsOH: p-toluenesulfonic acid; mp: melting point; EtSO 3 H: Ethanesulfonic acid; MeSO 3 H: methanesulfonic acid; ATP: adenosine triphosphate; HEPES: 4-hydroxyethylpiperazine; EGTA: ethylenebis(oxyethylenenitrilo)tetraacetic acid; MgCl 2 : Magnesium dichloride; MnCl 2 : manganese dichloride; DTT: dithiothreitol; DCC: dicyclohexylcarbodiimide; DMAP: 4-dimethylaminopyridine; DIEA: N,N-diisopropylethylamine; wt%: mass percentage; THF: tetrahydrofuran. Equipment and analytical methods
[0081] 1.1 X-ray powder diffractometer (XRPD) Model number: Bruker D8 advance X-ray diffraction instrument Test method: Approximately 10-20 mg of sample is used for XRPD detection. The detailed XRPD parameters are as follows: X-ray tube: Cu, kα, (λ=1.54056Å) X-ray tube voltage: 40kV, X-ray tube current: 40mA Divergence slit: 0.60mm Detector side slit: 10.50 mm Anti-scatter slit: 7.10mm Scanning range: 4~40deg Step diameter: 0.02 deg Step size: 0.12 seconds Sample pan rotation speed: 15 rpm 1.2 Differential Scanning Calorimeter (DSC) Model number: TAQ2000 differential scanning calorimeter Test method: A sample (~1 mg) is placed in a DSC aluminum pan and the test is performed with 50 mL / min of N 2 Under the above conditions, the sample is heated from 30°C to 300°C at a heating rate of 10°C / min. 1.3 Thermal Gravimetric Analyzer (TGA) Model number: TA Q5000 Thermogravimetric analyzer Test method: The sample (2-5 mg) is placed in a TGA platinum pan and the test is performed with 25 mL / min of N 2 Under the above conditions, the sample is heated from 30°C (room temperature) to 300°C at a heating rate of 10°C / min or until the weight loss is 20%. [Brief description of the drawings]
[0082] [Figure 1] (I) XRPD pattern of crystalline form A of compound using Cu-Kα radiation. [Diagram 2] (I) DSC pattern of crystalline form A of the compound. [Diagram 3] (I) TGA pattern of crystalline form A of compound. [Figure 4] (I) XRPD pattern of the B crystalline form of the compound with Cu-Kα radiation. [Diagram 5](I) DSC pattern of crystalline form B of the compound. [Figure 6] (I) TGA pattern of crystalline form B of compound. [Figure 7] (I) XRPD pattern of the C crystalline form of the compound with Cu-Kα radiation. [Figure 8] (I) DSC pattern of the C crystalline form of compound. [Figure 9] (I) TGA pattern of the C crystalline form of compound. [Figure 10] (I) XRPD pattern with Cu-Kα radiation of the D crystalline form of the compound. [Figure 11] (I) DSC pattern of the D crystalline form of the compound. [Figure 12] (I) TGA pattern of crystalline form D of compound. [Figure 13] (I) XRPD pattern with Cu-Kα radiation of the E crystalline form of the compound. [Figure 14] (I) DSC pattern of the E crystalline form of the compound. [Figure 15] (I) TGA pattern of the E crystalline form of the compound. [Figure 16] (I) XRPD pattern of the F crystalline form of the compound with Cu-Kα radiation. [Figure 17] (I) DSC pattern of the F crystal form of the compound. [Figure 18] (I) TGA pattern of the F crystalline form of compound. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0083] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples. Although the present specification describes the present invention in detail and discloses specific embodiments, it is obvious to those skilled in the art that various modifications and improvements can be made to the embodiments of the present invention without departing from the spirit and scope of the present invention.
[0084] Intermediate 1: [ka] It is prepared by referring to the synthesis method in patent WO2007126122.
[0085] Example 1: Compound of formula (I): [ka] Synthesis Route: [ka]
[0086] Step 1: Synthesis of compound 1-A 3-Butenylmagnesium bromide (1M, 55.12 mL) is added dropwise to a solution of 2-acetyl-6-bromopyridine (7.35 g, 36.74 mmol) in THF (150 mL) under nitrogen atmosphere at 0-15 °C, and the reaction is stirred at 10-20 °C for 3 h. The reaction is quenched by adding 100 mL of saturated ammonium chloride solution, separated to obtain an organic layer, which is further washed with 50 mL of saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated, and rotary evaporated to obtain a brown oil. The brown oil is further purified by silica gel column chromatography (PE / EA=7 / 1) to obtain 1-A. 1 HNMR (400 MHz, DMSO-d 6 )δ7.73(t, J=8.0Hz, 1H), 7.64(d, J=7.2Hz, 1H), 7.46(d, J=7.2Hz, 1H), 5.78~5. 7(m, 1H), 4.94~4.85(m, 2H), 2.07~2.01(m, 1H), 1.90~1.71(m, 3H), 1.41(s, 3H).
[0087] Step 2: Synthesis of compound 1-B To a mixture of 1-A (3.47 g, 13.55 mmol) and 1-C (3.01 g, 13.55 mmol) in dioxane (150 mL), N,N-dimethylethylenediamine (1.31 g, 14.90 mmol, 1.60 mL), copper iodide (2.58 g, 13.55 mmol, ) and potassium carbonate (2.62 g, 18.97 mmol) were added, and the mixture was purged with nitrogen three times. The mixture was stirred at 95 °C under nitrogen atmosphere for 1.5 h, and 200 mL of aqueous ammonia (28%) was added, and the mixture was extracted with ethyl acetate (300 mL x 2). The organic layers were combined, washed with 200 mL of saturated brine, dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure. The mixture was purified by silica gel column chromatography (PE / EA = 3 / 1) to obtain 1-B. 1 HNMR (400 MHz, DMSO-d 6 )δ9.02(s, 1H), 8.04(t, J=8.0Hz, 1H), 7.76(d, J=7.2Hz, 1H), 7.64(d, J=7.6Hz, 1H), 5.77~5.67(m, 2H), 5.01~4.79(m, 6H), 2.56(s, 3H), 2.15~2.11(m, 1H), 1.85~1.75(m, 2H), 1.70~1.60(m, 1H), 1.46(s, 3H).
[0088] Step 3: Synthesis of compound 1-D To a solution of 1-B (2.06 g, 5.18 mmol) in toluene (700 mL) is added Grubbs' second generation catalyst (1.32 g, 1.55 mmol) and the mixture is stirred at 80 °C under nitrogen atmosphere for 6 h. Grubbs' second generation catalyst (0.65 g, 0.775 mmol) is added and the mixture is stirred at 80 °C under nitrogen atmosphere for 3 h. Cool to room temperature, filter, and concentrate the filtrate to dryness to give a brown residue. Purify by silica gel column chromatography (PE / EA=1 / 1) to give 1-D. 1 HNMR (400 MHz, DMSO-d 6)δ9.07(s, 1H), 8.06(t, J=8.0Hz, 1H), 7.79(d, J=8.2Hz, 1H), 7.70(d, J=7.6Hz, 1H), 5.39~5.25 (m, 3H), 4.66(d, J=5.2Hz, 2H), 2.62(s, 3H), 2.40~1.95(m, 3H), 1.85~1.65(m, 1H)1.64(s, 3H).
[0089] Step 4: Synthesis of compound 1-E To a solution of compound 1-D (360 mg, 974.45 μmol) in toluene (35 mL) is added metachloroperbenzoic acid (265.09 mg, 1.31 mmol, 85% purity) and the reaction is stirred at 25 °C for 2 hours. 4-(4-methyl-1-piperazinyl)aniline (242.30 mg, 1.27 mmol) and N,N-diisopropylethylamine (503.76 mg, 3.90 mmol) are added to the reaction. The reaction is stirred at 25 °C for 12 hours. 25 mL of water is added to the reaction, stirred, and extracted with ethyl acetate (30 mL x 3). The organic phases are combined, washed once each with saturated sodium bicarbonate solution (30 mL) and saturated brine (30 mL), and dried over anhydrous sodium sulfate. Filter and concentrate in vacuo to obtain the crude product, which is separated by preparing a liquid phase (neutral) to obtain 1-E. 1 HNMR (400MHz, CDCl3)δ ppm 1.70(s, 3H) 1.78(brd, J=13.54Hz, 2H) 2.04(brd, J=6.54Hz, 1H) 2.08~2.23(m, 2H) 2.39(s, 3H) 2.62~2.64(m, 4H) 3.21~3.24(m, 4H) 4.2 4 (brs, 1H) 4.51 (brd, J=13.54Hz, 1H) 5.61~5.88 (m, 2H) 6.95 (d, J=9.04Hz, 2H) 7.49 (d, J=9.04Hz, 3H) 7.81~7.90 (m, 2H) 8.87 (s, 1H), MS m / z: 513.1 [M+H] + .
[0090] Step 5: Synthesis of Compounds of Formula (I) Compound 1-E (100 mg, 195.08 μmol) was subjected to SFC chiral resolution (chromatographic column: AD 250 × 50 mm ID, 10 μm mobile phase: A: supercritical CO 2 B: EtOH (0.1% NH 3 H 2 O), A:B=55:45 at 200 mL / min), retention time 21 min to obtain the compound of formula (I). 1 HNMR (400 MHz, CDCl 3 )δ ppm 1.60(s, 3H) 1.68(brs, 2H) 1.94(brd, J=7.04Hz, 1H) 2.00~2.20(m, 2H) 2.30(s, 3H) 2.52~2.55(m, 4H) 3.12~3.15(m, 4H) 4.24(brs, 1 H) 4.42 (brd, J=9.54Hz, 1H) 5.65 (brs, 2H) 6.85 (d, J=9.04Hz, 2H) 7.17 (s, 1H) 7.40 (d, J=9.04Hz, 2H) 7.69~7.81 (m, 2H) 8.77 (s, 1H). MS m / z: 513.1 [M+H] + .
[0091] Example 2: Preparation of Crystalline Form A of Compound of Formula (I) Approximately 50 mg of compound of formula (I) is added to each of different glass bottles, and 0.5 mL of acetone is added to each to form a suspension. The above suspension samples are placed in a thermostatic shaker (40°C) for testing. The suspension samples are shaken at 40°C for 2 days, centrifuged, the upper liquid is removed, and the remaining sample is placed in a vacuum oven (40°C) to dry overnight to obtain the crystalline form of compound A of formula (I).
[0092] Example 3: Preparation of crystalline form B of the compound of formula (I) Approximately 50 mg of compound of formula (I) is added to each of different glass bottles, and 0.3 mL of ethanol is added to each to form a suspension. The above suspension samples are placed in a thermostatic shaker (40°C) for testing. The suspension samples are shaken at 40°C for 2 days, centrifuged, the upper liquid is removed, and the remaining sample is placed in a vacuum oven (40°C) to dry overnight to obtain the crystalline form of compound B of formula (I).
[0093] Example 4: Preparation of crystalline form C of the compound of formula (I) Approximately 50 mg of compound of formula (I) is added to each of different glass bottles, and 0.2 mL of methanol is added to each to form a suspension. The above suspension samples are placed in a thermostatic shaker (40°C) for testing. The suspension samples are shaken at 40°C for 2 days, centrifuged, the upper liquid is removed, and the remaining sample is placed in a vacuum oven (40°C) to dry overnight to obtain the crystalline form of compound C of formula (I).
[0094] Example 5: Preparation of crystalline form D of the compound of formula (I) Approximately 50 mg of compound of formula (I) is added to each of different glass bottles, and 0.4 mL of methanol / water (1 / 1) is added to each to form a suspension. The above suspension samples are placed in a thermostatic shaker (40°C) for testing. The suspension samples are shaken at 40°C for 2 days, centrifuged, the upper liquid is removed, and the remaining sample is placed in a vacuum oven (40°C) to dry overnight to obtain the crystalline form of compound D of formula (I).
[0095] Example 6: Preparation of crystalline form E of the compound of formula (I) Approximately 50 mg of compound of formula (I) is added to each of different glass bottles, and 0.5 mL of acetonitrile is added to each to form a suspension. The above suspension samples are placed in a thermostatic shaker (40°C) for testing. The suspension samples are shaken at 40°C for 2 days, centrifuged, the upper liquid is removed, and the remaining sample is placed in a vacuum oven (40°C) to dry overnight to obtain the crystalline form of compound E of formula (I).
[0096] Example 7: Preparation of the F crystalline form of the compound of formula (I) Add 134.19 g of compound of formula (I) to a 1 L three-neck flask filled with 560 mL of MeOH at 25-26 °C, stir and heat to 55-65 °C in an oil bath, and after 20 minutes, keep the internal temperature at 47 °C-53 °C. Keep warm and stir for 72 hours. Stop heating and allow to cool naturally with stirring for 1 hour to reach 27 °C. Leave to stand for 18 hours, filter, and further wash the filter cake with 30 mL of MeOH. Dry the filter cake in vacuum at 60 °C for 48 hours. Obtain the crystalline form of compound F of formula (I).
[0097] Experimental Example 1: Stability test of the solid state of the F crystal form of the compound of formula (I) under high temperature, high humidity and lighting conditions Based on the influencing factors and accelerated test conditions, accurately weigh out about 5 mg of the F crystal form of compound of formula (I), place it in a dry and clean glass bottle, spread it in a double layer, and place it under the influencing factor test conditions (60°C, 92.5% RH (relative humidity)) and accelerated conditions (40°C / 75% RH and 60°C / 75% RH) as a formal test sample, place the sample completely exposed, cover it with aluminum foil paper, and puncture a small hole. Also, place a small amount of each sample in a 40mL glass sample bottle to measure the state of the crystal form under the same conditions. Sampling analysis was performed on the 5th day, 10th day, and 1 month, and the analysis method is shown in Table 7, and the analysis results are shown in Table 8. The sample placed under light irradiation (visible light 1200000 Lux, ultraviolet light 200W) conditions is the sample placed completely exposed at room temperature.
[0098] Table 7: High performance liquid chromatography analysis method for related substances [Table 7] Table 8: Content and related substance analysis results of the solid stability sample of the F crystalline form of the compound of formula (I) (5 days, 10 days, 1 month) [Table 8]
[0099] Conclusion: The crystalline form of compound F of formula (I) has good physical stability, with no change in the crystalline form of the raw material compound in one month of solid state impact factor and accelerated testing. In the related substance analysis, the impurities increased slightly at high temperature (60°C) and accelerated conditions (60°C / 75%RH), while the total amount of impurities changed little under other conditions, showing slight sensitivity to temperature.
[0100] Experimental conclusion: The present invention has high stability of the crystal form and is easy to manufacture the pharmaceutical product.
[0101] Experimental Example 2: In vitro enzymatic inhibitory activity of compounds of formula (I) The experimental tests will be carried out at Eurofins and the experimental results will be provided by the company.
[0102] The test system contained 20 mM Tris-HCl, pH 8.5, 0.2 mM EDTA, 500 μM polypeptide substrate (LSNLYHQGKFLQTFCGSPLYRRR), 10 mM magnesium acetate, and 10 μM [γ- 33 Add [P]-ATP (strength is approximately 500 cpm / pmol). 2+ After adding the mixture of ATP and ATP, the reaction is started and incubated at room temperature for 40 min. The reaction is stopped by adding 3% phosphate buffer. 10 μL of the reaction solution is filtered through a continuous filter P30, washed three times with 75 mM phosphate buffer, washed once with methanol, and washed for 5 min each time. After drying, the value is read by scintillation counting. The test results are shown in Table 9.
[0103] Table 9 In vitro screening test results of the compounds of the present invention (IC 50 ) [Table 9]
[0104] Test Example 3 In vitro permeability test of the compound of the present invention In the study, MDR1-MDCK II cells licensed by the laboratory of Piet Borst of the Netherlands Cancer Institute are used, which are Madin-Darby canine kidney cells transfected with human multiresistance gene (MDR1), and the cells can stably express the efflux transporter P-glycoprotein (P-gp), so they are applicable to the screening of P-gp substrates or inhibitors, and are predicted to have high permeability through the efflux barriers of the compounds, such as the duodenum, blood-brain barrier, hepatocyte nucleus and renal unit. The inventors use the 5th-35th generation MDR1-MDCKII cells for the permeability study.
[0105] MDR1-MDCKII cells were cultured in α-MEM medium (α-Minimum Essential Media) at 37 ± 1°C and 5% CO 2 and saturated relative humidity. Cells were then seeded into BD Transwell-96 cell well plates at a seeding density of 2.3 × 10 5 Cells / cm 2 The cells are then placed in a carbon dioxide incubator and cultured for 4 to 7 days before being used in the transport experiment. The method for preparing the α-MEM medium is as follows.
[0106] The liquid medium was prepared by dissolving the powder (α-MEM powder from Gibco, Cat#:11900) in pure water and adding L-(L-glutamine) and NaHCO 3 The medium is obtained by adding 10% FBS (fetal bovine serum), 1% PS (double antibody), and 1% NEAA when used later to make a complete medium. The ingredients of α-MEM medium are shown in Table 10.
[0107] Table 10 αMEM (1L×) raw material composition table [Table 10]
[0108] The dose concentration of AZD1775 (or the compound of the present invention) and Digoxin was 2 μM, dosed in two directions (AB and BA directions), and each was performed in two duplicate wells. The test concentrations of Fenoterol and Propranolol were both 2 μM, dosed in one direction (AB direction), and each was performed in two duplicate wells.
[0109] The solutions to be used are pre-incubated in a water bath at 37±1°C for 30 minutes. The dosing and receptor solutions are added to the corresponding well positions of the cell well plate (75 and 250 μL of sample are added to each apical and basal well, respectively) to initiate the bidirectional transport experiment. After sample addition, the cell well plate is incubated at 37±1°C, 5% CO 2 and place in an incubator at saturated relative humidity for 150 minutes. Sample collection information is shown in Table 11.
[0110] Table 11. Sample Collection Information [Table 11]
[0111] Note: T 0 indicates the first dosing solution sample.
[0112] All samples were vortexed and then centrifuged at 3220 g for 10 min, and an appropriate volume of the supernatant was transferred to a sample analysis plate. After sealing the plate, the samples were stored at 2-8°C if not analyzed immediately, and then analyzed by LC-MS / MS.
[0113] After the transport experiment is completed, the integrity of MDR1-MDCKII cells is tested by Lucifer Yellow Rejection Assay. After 30 min incubation with Lucifer Yellow solution, Lucifer Yellow samples are collected and the 2e plate reader detects the relative fluorescence unit (RFU) of Lucifer Yellow in the samples at 425 / 528 nm (excitation / emission) spectrum.
[0114] The test sample AZD1775 (or the compound of the present invention) and the control samples Fenoterol, Propranolol and Digoxin are analyzed semi-quantitatively, and the ratio of the peak area of the analyte to that of the internal standard is taken as the concentration of the control sample.
[0115] The experimental results are shown in Table 12.
[0116] Table 12 Transmission rate (10 -6 cm / s) [Table 12] Test conclusion: The permeation properties of the compounds of formula (I) are significantly improved over AZD1775, lending themselves to biopharmaceutical applications.
[0117] Experimental Example 4: Compound Pharmacokinetic Evaluation This experiment aims to study the pharmacokinetic profile of AZD1775 (or a compound of the invention) in plasma of female Balb / c nude mice after a single intravenous and a single oral dose.
[0118] 12 mice (provided by Lingchuan) are randomly divided into two groups, with 6 females in each group, and samples are collected by alternate blood sampling. All animals in the intravenous group are intravenously injected with 1mg / kg AZD1775 (or the compound of the present invention), and the solvent preparation is a clear solution of 5% HP-betaCD (Kunshan Raisk Chemical Raw Materials Co., Ltd.) containing 0.2mg / mL AZD1775 (or the compound of the present invention). Animals in the oral group are intragastrically administered with 10mg / kg AZD1775 (or the compound of the present invention), and the solvent preparation is a uniform suspension of 0.5% methylcellulose containing 1mg / mL AZD1775 (or the compound of the present invention).
[0119] For animals in the intravenous group, plasma samples are collected at 9 time points after administration: 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours; for animals in the oral group, plasma samples are collected at 8 time points after administration: 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours; the samples are analyzed by LC-MS / MS to obtain plasma concentration data of AZD1775 (or the compound of the present invention), and pharmacokinetic parameters such as peak concentration, time to peak, elimination rate, half-life, area under the drug-time curve, bioavailability, etc. are calculated.
[0120] The experimental results are shown in Table 13.
[0121] Table 13. Pharmacokinetic study results [Table 13] Experimental conclusion: The compound of formula (I) can significantly improve several indexes of mouse pharmacokinetics compared with AZD1775, and the in vivo elimination rate, half-life, in vivo concentration integral and bioavailability all have obvious advantages.
[0122] Experimental Example 5: In vivo studies (1) In vivo pharmacodynamic study of the compound against a nude mouse model of subcutaneous xenograft tumors of human colon cancer LoVo cells (BALB / c) Experimental Method: The experimental animals selected (provided by Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd.) were 6-8 week-old BALB / c nude mice weighing 18-22 g.
[0123] Human colon cancer LoVo cells were cultured in monolayer in vitro in Ham's F-12 medium supplemented with 10% fetal bovine serum, 100 U / mL penicillin, 100 μg / mL streptomycin, and 2 mM glutamine at 37°C in 5% CO. 2 The cells were cultured in 0.1 mL (10 × 10 6 LoVo cells (1000 cells) were inoculated subcutaneously into the right dorsal region of each nude mouse, and the average tumor volume was 213 mm 3 When the tumor volume reached 100 mg / kg, group administration was started. The intragastric dose was 40 mg / kg, twice daily. The experimental endpoint was to determine whether tumor growth was inhibited, delayed, or cured. The tumor diameter was measured twice a week using a cursor scale. The formula for calculating tumor volume was V=0.5a×b. 2 where a and b represent the long and short diameters of the tumor, respectively.
[0124] The tumor inhibition effect of the compound was evaluated by TGI (%) or relative tumor growth rate T / C (%). TGI (%) reflects the tumor growth inhibition rate. Calculation of TGI (%): TGI (%) = [1-(mean tumor volume at the end of treatment of a treatment group-mean tumor volume at the start of treatment of the treatment group) / (mean tumor volume at the end of treatment of the solvent control group-mean tumor volume at the start of treatment of the solvent control group)] x 100%.
[0125] The final experimental results after 16 days of administration are shown in Table 14.
[0126] Table 14. Efficacy test results of mouse model with xenograft tumor of human colon cancer LoVo cells [Table 14]
[0127] Conclusion: The compounds of the present invention can significantly improve the inhibitory effect on tumors in mice compared with AZD1775, and the chirality of the compounds has an unexpected effect on the in vivo efficacy.
[0128] (2) In vivo pharmacodynamic study of the compound in a subcutaneously transplanted BxPC-3 tumor model of human pancreatic cancer in BALB / c nude mice Experimental Method: The experimental animals selected were BALB / c nude mice aged 6-8 weeks, weighing 18-22 g.
[0129] The 10th generation of BxPC-3 cells was cultured in vitro in a monolayer in RPMI1640 medium (manufacturer: Gibco, product number: 22400-089) supplemented with 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin at 37°C in 5% CO. 2 The cells were cultured and passaged four times. The passage method was to passage twice a week with pancreatic enzyme-EDTA digestion. When the cell saturation reached 80%-90%, the cells were digested with pancreatin-EDTA, counted, and resuspended in PBS at a density of 5 × 10 7 Each animal was injected with 0.1 mL (5 × 10 6 ) of BxPC-3 cells, the average tumor volume was 153 mm 3 When the tumor volume reaches 100 mg / kg, the mice are randomly divided into groups based on tumor volume and the administration is started. Intragastric administration dose: 25 mg / kg, once daily.
[0130] The experimental endpoint is to consider whether tumor growth is inhibited, delayed or cured. The tumor diameter was measured twice a week by cursor scale. The tumor inhibition effect of the compound was evaluated by TGI (%) or relative tumor growth rate T / C (%). TGI (%) reflects the tumor growth inhibition rate. Calculation of TGI (%): TGI (%) = [1-(mean tumor volume at the end of administration of a certain treatment group-mean tumor volume at the start of administration of the treatment group) / (mean tumor volume at the end of treatment of the solvent control group-mean tumor volume at the start of treatment of the solvent control group)] x 100%.
[0131] The final experimental results after 27 days of administration are shown in Table 15.
[0132] Table 15. Efficacy test results of mouse model with xenograft tumor of human pancreatic cancer BxPC-3 cells [Table 15]
[0133] Conclusion: As can be seen from Table 15, the compound of formula (I) can significantly improve the inhibitory effect on tumors in mice compared with AZD1775.
[0134] (3) In vivo antitumor efficacy study of compounds against animal transplanted tumor models of CT26 mouse colon cancer cells Experimental Method: The experimental animals selected were 7-week-old female BALB / c nude mice weighing 16-20 g.
[0135] Cells: Mouse colon cancer CT26 cells (Cell Bank of the Committee for the Preservation of Classical Cultures, Chinese Academy of Sciences) were cultured in monolayer in vitro. The culture conditions were RPMI-1640 containing 10% fetal bovine serum at 37°C and 5% CO. 2 The cells were cultured in an incubator. They were routinely digested with pancreatic enzyme-EDTA and passaged. When the cells were in the exponential growth phase and reached 80%-90% cell saturation, they were received, counted, and inoculated. The cells were then resuspended in 0.1 mL of DPBS (3 × 10 5 Each mouse was subcutaneously inoculated with 1000 CT26 cells (containing 1000 CT26 cells) into the right dorsal region until the tumor volume reached an average of 50–70 mm. 3 When the tumor volume reaches 100 mg / kg, the subjects will be randomly assigned to groups based on tumor volume and administered the following: Intragastric dose: 30 mg / kg, twice daily.
[0136] The experimental endpoint is to consider whether tumor growth is inhibited, delayed or cured. The tumor diameter was measured twice a week by cursor scale. The tumor inhibition effect of the compound was evaluated by TGI (%) or relative tumor growth rate T / C (%). TGI (%) reflects the tumor growth inhibition rate. Calculation of TGI (%): TGI (%) = [1-(mean tumor volume at the end of administration of a certain treatment group-mean tumor volume at the start of administration of the treatment group) / (mean tumor volume at the end of treatment of the solvent control group-mean tumor volume at the start of treatment of the solvent control group)] x 100%.
[0137] The final experimental results after 18 days of administration are shown in Table 16.
[0138] Table 16. In vivo efficacy test results of the mouse colon cancer CT26 cell homograft tumor model [Table 16]
[0139] Conclusion: As can be seen from Table 16, the compound of formula (I) can significantly improve the inhibitory effect on tumors in mice compared with AZD1775.
Claims
1. The X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at the following 2-theta angles: 5.71±0.2°, 12.68±0.2°, 15.32±0.2°, 23.61±0.2° and 25.68±0.2°. A crystalline form of compound of formula (I). 【Chemistry 1】
2. 2. The crystalline form A of claim 1, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.71±0.2°, 12.68±0.2°, 15.32±0.2°, 18.04±0.2°, 19.72±0.2°, 21.44±0.2°, 23.61±0.2°, and 25.68±0.2°.
3. The following XRPD pattern analysis data: 【Table 1】 3. The crystalline form A of claim 2, having the formula:
4. 4. The crystalline form A of any one of claims 1 to 3, wherein the differential scanning calorimetry curve (DSC) has the onset of one endothermic peak at 34.95±3°C, 174.75±3°C and 219.12±3°C, respectively.
5. 4. The crystalline form A of any one of claims 1 to 3, wherein the thermogravimetric analysis curve (TGA) reaches a weight loss of 0.7367% at 70.33±3°C and a weight loss of 3.123% at 209.42±3°C.
6. The X-ray powder diffraction (XRPD) pattern of the B crystalline form of compound of formula (I) has characteristic diffraction peaks at the following 2-theta angles: 5.58±0.2°, 11.71±0.2°, 12.44±0.2°, 18.64±0.2° and 22.16±0.2°. 【Chemistry 2】
7. 7. The crystalline form B of claim 6, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.58±0.2°, 11.71±0.2°, 12.44±0.2°, 14.48±0.2°, 15.13±0.2°, 18.64±0.2°, 22.16±0.2°, and 26.33±0.2°.
8. The following XRPD pattern analysis data: 【Table 2】 8. The crystalline form B of claim 7, having the formula:
9. 9. The crystalline form B of any one of claims 6 to 8, wherein the differential scanning calorimetry curve (DSC) has the onset of one endothermic peak at 42.88±3°C, 198.79±3°C and 222.36±3°C, respectively.
10. 9. The crystalline form B of any one of claims 6 to 8, wherein the thermogravimetric analysis curve (TGA) reaches a weight loss of 3.265% at 64.21±3°C and a weight loss of 1.516% at 243.05±3°C.
11. The X-ray powder diffraction (XRPD) pattern of the C crystalline form of compound of formula (I) has characteristic diffraction peaks at the following 2θ angles: 5.05±0.2°, 5.58±0.2° and 12.44±0.2°. 【Chemistry 3】
12. 12. The C crystalline form of claim 11, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.05±0.2°, 5.58±0.2°, 12.44±0.2°, 15.91±0.2°, 16.68±0.2°, 17.61±0.2°, 22.19±0.2°, and 26.37±0.2°.
13. The following XRPD pattern analysis data: 【Table 3】 13. The C crystalline form of claim 12, having
14. 14. The C crystalline form of any one of claims 11 to 13, wherein the differential scanning calorimetry curve (DSC) has the onset of one endothermic peak at 37.06±3°C, 189.16±3°C, and 218.61±3°C, respectively.
15. 14. The C crystalline form of any one of claims 11 to 13, wherein the thermogravimetric analysis curve (TGA) reaches a weight loss of 2.211% at 64.98±3°C and a weight loss of 1.127% at 224.71±3°C.
16. The X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at the following 2θ angles: 5.22±0.2°, 15.99±0.2°, 16.57±0.2°, 17.08±0.2° and 21.22±0.2°, D crystalline form of compound of formula (I). 【Chemistry 4】
17. 17. The D crystalline form of claim 16, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.22±0.2°, 15.18±0.2°, 15.99±0.2°, 16.57±0.2°, 17.08±0.2°, 18.60±0.2°, 21.22±0.2°, and 21.89±0.2°.
18. The following XRPD pattern analysis data: 【Table 4】 20. The D crystalline form of claim 17, having the formula:
19. 19. The D crystalline form of any one of claims 16 to 18, wherein the differential scanning calorimetry curve (DSC) has the onset of one endothermic peak at 56.07±3°C, 193.93±3°C, and 216.54±3°C, respectively.
20. 19. The D crystalline form of any one of claims 16 to 18, wherein the thermogravimetric analysis curve (TGA) reaches a weight loss of 1.977% at 79.35±3°C and a weight loss of 1.589% at 223.66±3°C.
21. The X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at 2θ angles: 8.65±0.2°, 14.22±0.2° and 24.58±0.2°, of the E crystalline form of compound of formula (I). 【Chemistry 5】
22. 22. The crystalline form E of claim 21, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 8.65±0.2°, 11.41±0.2°, 13.13±0.2°, 14.22±0.2°, 17.35±0.2°, 18.34±0.2°, 20.39±0.2°, 20.94±0.2°, and 24.58±0.2°.
23. The following XRPD pattern analysis data: 【Table 5】 23. The crystalline form E of claim 22, having the formula:
24. 24. The crystalline form E of any one of claims 21 to 23, wherein the differential scanning calorimetry curve (DSC) has onsets of one endothermic peak at 121.57±3°C, 197.26±3°C and 217.23±3°C, respectively, and peak values of one exothermic peak at 168.31±3°C and 212.95±3°C, respectively.
25. 24. The E crystalline form of any one of claims 21 to 23, wherein the thermogravimetric analysis curve (TGA) reaches a weight loss of 6.775% at 143.31±3°C and a weight loss of 0.3184% at 213.62±3°C.
26. The X-ray powder diffraction (XRPD) pattern of the F crystalline form of compound of formula (I) has characteristic diffraction peaks at the following 2θ angles: 5.06±0.2°, 10.98±0.2°, 15.13±0.2°, 15.91±0.2°, 16.68±0.2° and 17.63±0.2°. 【Chemistry 6】
27. 27. The crystalline form F of claim 26, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.06±0.2°, 8.34±0.2°, 10.98±0.2°, 15.13±0.2°, 15.91±0.2°, 16.68±0.2°, 17.63±0.2°, and 18.87±0.2°.
28. The following XRPD pattern analysis data: 【Table 6】 28. The crystalline form F of claim 27, having the formula:
29. 29. The F crystalline form of any one of claims 26-28, wherein a differential scanning calorimetry curve (DSC) has the onset of one endothermic peak at 48.69±3°C and 225.26±3°C, respectively.
30. 29. The F crystalline form of any one of claims 26 to 28, wherein the thermogravimetric analysis curve (TGA) reaches a weight loss of 3.404% at 100±3°C.
31. A composition for treating a Wee1 related disease comprising the crystalline form A of any one of claims 1 to 5, the crystalline form B of any one of claims 6 to 10, the crystalline form C of any one of claims 11 to 15, the crystalline form D of any one of claims 16 to 20, the crystalline form E of any one of claims 21 to 25, or the crystalline form F of any one of claims 26 to 30.
32. (a) adding the compound of formula (I) to an alcoholic solvent, which is methanol, stirring and heating to 55-65° C. in an oil bath; (b) stirring at 47°C to 53°C for 72 hours; (c) stopping the heating and allowing the mixture to cool naturally for 1 hour while stirring to reach 27°C; (d) standing for 18 hours, filtering and washing the filter cake with methanol; Step (e) of vacuum drying at 60° C. for 48 hours; A process for preparing the F crystalline form of compound of formula (I) according to any one of claims 26 to 30, comprising the steps (a) to (e) in that order.
33. A pharmaceutical composition comprising the crystalline form A of any one of claims 1-5, the crystalline form B of any one of claims 6-10, the crystalline form C of any one of claims 11-15, the crystalline form D of any one of claims 16-20, the crystalline form E of any one of claims 21-25, or the crystalline form F of any one of claims 26-30.
Citation Information
Patent Citations
JP2213673B
Dihydropyrazolopyrimidinone derivatives
US20070254892A1
Tricyclic inhibitors of kinases
US20120220572A1
Dihydropyrazolopyrimidinone derivatives
WO2007126122A1
Polymorph of dihydropyrazolopyrimidinone derivative as WEEL kinase.inhibitor
WO2008133866A1
